Abstract
The knowledge and awareness of health professionals and patients surrounding black box warnings are still gaping. Our target is to find solutions to prevent potential side effects and severe interactions. Black box warnings are the strongest drug safety warnings issued by regulatory authorities, highlighting the potential risks associated with specific medications. However, there is often limited understanding and awareness of these warnings among both healthcare providers and patients, which can lead to inadequate risk management and patient safety. Therefore, closing knowledge gaps and proposing strategies for improving awareness and reducing adverse events related to medications with black box warnings is crucial. As we witness an unprecedented surge in drug discoveries, especially biological drugs for immunological disorders and cancer therapy, growing dramatically and receiving approvals by the FDA, the landscape of healthcare is rapidly evolving. With the remarkable advancements in immunotherapy, particularly the proliferation of monoclonal antibody drugs, we are witnessing a paradigm shift in the treatment of various conditions. However, this surge in drug approvals has brought forth a crucial concern - the increasing prevalence of Black Box Warnings associated with many of these drugs. A Black Box Warning, recognized as the most critical indication of potential serious side effects by the FDA, is typically issued post-marketing. This revelation highlights a significant gap in our understanding, particularly in terms of knowledge and adherence to these warnings by healthcare professionals, including physicians and pharmacists. We suggest the black box warning must have a barcode or logo on the outer pack of the drug if it has a black box warning, as this will give an alert for serious side effects or interactions for patient safety and provide an alert for physicians, patients, and pharmacists. Also, we suggest the warning black box drugs must be registered as notes in prescriptions either written or electronic, also registered in electronic prescriptions as a black box with a warning alarm in front of any drug carrying a black box warning, and also in medical records at hospitals and in pharmacist and patient files, as this enhances health outcomes and avoids serious side effects for patient safety.
Reference6 articles.
1. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products [Internet]. 2011 [cited Sept. 2015] Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm065010.htm.
2. Fornaro M, Anastasia A, Valchera A, Carano A, Orsolini L, Vellante F, Rapini G, Olivieri L, Di Natale S, Perna G, Martinotti G, Di Giannantonio M, De Berardis D. The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits? Front Psychiatry. 2019 May 3; 10:294. doi: 10.3389/fpsyt.2019.00294.
3. Hagan JB, Ender E, Divekar RD, Pongdee T, Rank MA. Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies. Mayo Clin Proc Innov Qual Outcomes. 2021 Dec 28;6(1):69-76. doi: 10.1016/j.mayocpiqo.2021.11.009. PMID: 35024565; PMCID: PMC8724853.
4. Smollin CG, Fu J, Levin R. Recognition and Knowledge of Medications with Black Box Warnings Among Pediatricians and Emergency Physicians. J Med Toxicol. 2016 Jun;12(2):180-4. doi: 10.1007/s13181-015-0519-3.
5. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010 Jan 11;170(1):96-103. doi: 10.1001/archinternmed.2009.456. PMID: 20065205; PMCID: PMC4598075.